Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe
- Characterizing RLT-induced immune modulation and its role in tumor sensitization and resistance
- Evaluating preclinical combinations of RLT with immune checkpoint inhibitors, CAR-T cells, and emerging immunotherapies
- Leveraging synergistic immune– radiobiological mechanisms to enhance depth and durability of response